Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Kisspeptins inhibit human airway smooth muscle proliferation
Niyati A. Borkar, Nilesh Sudhakar Ambhore, Rama Satyanarayana Raju Kalidhindi, Christina M. Pabelick, Y.S. Prakash, Venkatachalem Sathish
Niyati A. Borkar, Nilesh Sudhakar Ambhore, Rama Satyanarayana Raju Kalidhindi, Christina M. Pabelick, Y.S. Prakash, Venkatachalem Sathish
View: Text | PDF
Research Article Muscle biology Pulmonology

Kisspeptins inhibit human airway smooth muscle proliferation

  • Text
  • PDF
Abstract

Sex and gender disparity in asthma is recognized and suggests a modulatory role for sex steroids, particularly estrogen. However, there is a dichotomous role for estrogen in airway remodeling, making it unclear whether sex hormones are protective or detrimental in asthma and suggesting a need to explore mechanisms upstream or independent of estrogen. We hypothesize that kisspeptin (Kp)/KISS1R signaling serves this role. Airway smooth muscle (ASM) is a key structural cell type that contributes to remodeling in asthma. We explored the role of Kp/KISS1R in regulating ASM proliferation. We report potentially novel data indicating that Kp and KISS1R are expressed in human airways, especially ASM, with lower expression in ASM from women compared with men and lower in patients with asthma compared with people without asthma. Proliferation studies showed that cleaved forms of Kp, particularly Kp-10, mitigated PDGF-induced ASM proliferation. Pharmacological inhibition and shRNA knockdown of KISS1R increased basal ASM proliferation, which was further amplified by PDGF. The antiproliferative effect of Kp-10 in ASM was mediated by inhibition of MAPK/ERK/Akt pathways, with altered expression of PCNA, C/EBP-α, Ki-67, cyclin D1, and cyclin E leading to cell cycle arrest at G0/G1 phase. Overall, we demonstrate the importance of Kp/KISS1R signaling in regulating ASM proliferation and a potential therapeutic avenue to blunt remodeling in asthma.

Authors

Niyati A. Borkar, Nilesh Sudhakar Ambhore, Rama Satyanarayana Raju Kalidhindi, Christina M. Pabelick, Y.S. Prakash, Venkatachalem Sathish

×

Figure 5

Kps and human ASM cell proliferation.

Options: View larger image (or click on image) Download as PowerPoint
Kps and human ASM cell proliferation.
The effect of different Kps (namel...
The effect of different Kps (namely, Kp-10, Kp-13, Kp-14, and Kp-54) on basal and PDGF-induced cell proliferation in ASM cells of people without asthma was evaluated using MTT assay (A). Among the 4 forms of Kps (1 μM), Kp-10 significantly blunted PDGF-induced ASM cell proliferation. Furthermore, the effect of different log concentrations of Kp-10 (100 nM, 1 μM, and 10 μM) on regulating PDGF-induced ASM proliferation was determined (B). The relative level of LDH was measured in ASM cell supernatants to evaluate the cytotoxicity of the selected concentration (1 μM) of Kp-10 (C). The treatment groups did not show cytotoxicity after 24 hours of exposure when compared with the negative control group. Data are reported as a minimum to maximum of 7 to 8 individual ASM samples from donors without asthma and analyzed using 1-way ANOVA followed by Tukey’s post hoc test. **P < 0.01, ***P < 0.001 vs. respective vehicle; #P < 0.05, ###P< 0.001 vs. PDGF-exposed groups.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts